Abstract:Endothelial dysfunction predisposing to cardiovascular diseases is defined as an imbalance in the production of vasodilating factors, such as nitric oxide (NO), and vasoconstrictive factors. To insure its physiological role, NO, a radical with very short half-life, requires to be stored and transported to its action site. S-nitrosothiols (RSNOs) like S-nitrosoglutathione (GSNO) represent the main form of NO storage within the vasculature. The NO store formed by RSNOs is still bioavailable to trigger vasorelaxation. In this way, RSNOs are an emerging class of NO donors with a potential to restore NO bioavailability within cardiovascular disorders. The aim of this study was to compare S-nitrosothiols ability, formed of peptide (glutathione) like the physiologic GSNO or derived from amino acids (cysteine, valine) like the synthetics S-nitroso-N-acetylcysteine (NACNO) and S-nitroso-N-acetylpenicillamine (SNAP), respectively, to produce a vascular store of NO either in endothelium-intact or endothelium-removed aortae in order to evaluate whether RSNOs can be used as therapeutics to compensate endothelial dysfunction. Sodium nitroprusside (SNP), a marketed drug already in clinics, was used as a non-RSNO NO-donor. Endothelium-intact or endothelium-removed aortae, isolated from normotensive Wistar rats, were exposed to RSNOs or SNP. Then, NO-derived (NOx) species, representing the NO store inside the vascular wall, were quantified using the diaminonaphthalene probe coupled to mercuric ions. The bioavailability of the NO store and its ability to induce vasodilation was tested using N-acetylcysteine, then its ability to counteract vasoconstriction was challenged using phenylephrine (PHE). All the studied RSNOs were able to generate a NO store materialized by a three to five times increase in NOx species inside aortae. NACNO was the most potent RSNO to produce a vascular NO store bioavailable for vasorelaxation and the most efficient to induce vascular hyporeactivity to PHE in endothelium-removed aortae. GSNO and SNAP were equivalent and more efficient than SNP. In endothelium-intact aortae, the NO store was also formed whereas it seemed less available for vasorelaxation and did not influence PHE-induced vasoconstriction. In conclusion, RSNOs - NACNO in a better extent - are able to restore NO bioavailability as a functional NO store within the vessel wall, especially when the endothelium is removed. This was associated with a hyporeactivity to the vasoconstrictive agent phenylephrine. Treatment with RSNOs could present a benefit to restore NO-dependent functions in pathological states associated with injured endothelium.

Nitric oxide-triggering activity of gold-, platinum- and cerium oxide-nanozymes from S-nitrosothiols and diazeniumdiolates

Gold Nanorod-Based Nanoplatform Catalyzes Constant NO Generation and Protects from Cardiovascular Injury

S-nitrosocysteamine-functionalised porous graphene oxide nanosheets as nitric oxide delivery vehicles for cardiovascular applications

A Redox Modulatory Sod Mimetic Nanozyme Prevents The Formation of Cytotoxic Peroxynitrite And Improves Nitric Oxide Bioavailability in Human Endothelial Cells

Recent Advances in Functional Nanomaterials for Catalytic Generation of Nitric Oxide: A Mini Review

Novel Ruthenium‐based Nitrosyl Complexes: NO Donation and Vasorelaxant Potentials for Cardiovascular Therapeutics

Nitric Oxide (No)-Releasing Macromolecules: Rational Design and Biomedical Applications

Advanced Nitric Oxide Generating Nanomedicine for Therapeutic Applications

Tuning Cellular Biological Functions Through the Controlled Release of NO from a Porous Ti-MOF

Biomimetic Activation of N-Nitrosamides with Red Light-Triggered Nitric Oxide Release via Mediated Electron Transfer

Nitric Oxide-Releasing Platforms for Treating Cardiovascular Disease

Nitric Oxide-Releasing Macromolecular Systems in Anticoagulant Therapeutics

NOS-like activity of CeO2 nanozymes contributes to diminishing the vascular plaques

Recent Advancements in Polymeric N-Nitrosamine-Based Nitric Oxide (NO) Donors and their Therapeutic Applications

An Orthoformate-Bridged Bis-diazeniumdiolates: Enhanced Nitric Oxide Loading and Released NO under Physiological Conditions

Vitamin B3 metal-organic frameworks as potential delivery vehicles for therapeutic nitric oxide

Advancements in NADH Oxidase Nanozymes: Bridging Nanotechnology and Biomedical Applications

Nanostructure for Nitric Oxide Electrochemical Sensing

S-Nitrosothiols as potential therapeutics to induce a mobilizable vascular store of nitric oxide to counteract endothelial dysfunction

Nitric Oxide‐Releasing Macromolecular Systems in Anticoagulant Therapeutics

One-electron reduction triggered nitric oxide release for ischemia-reperfusion protection